29
November 12, 2025 | Though gender equity efforts in research have made strides, progress has plateaued. Roughly two-thirds of pivotal clinical trials leading to the U.S. Food and Drug Administration (FDA) drug approvals now include women at rates proportional to their disease burden, but the problem is “fundamental issues in not considering female biology,” according to Sophie Zaaijer, Ph.D., clinical and translational scientist at the University California Irvine and Riverside.
“We are stuck in treating women as if they are mini…